Navigation Links
Agency Take-up Soars of Agnitio's Leading Pull Marketing Platform for the Healthcare Industry
Date:1/17/2013

COPENHAGEN, Denmark, January 17, 2013 /PRNewswire/ --

  • 50% jump in licences over the last two months
  • Used by leading global agencies

A rapid increase in interest around Agnitio's closed loop marketing platform, has seen the global pharmaceutical marketing company experience a 50% increase in the number of licences granted to advertising, marketing and creative agencies in the last two months alone.

     (Logo: http://photos.prnewswire.com/prnh/20120924/562917-a)
     (Photo: http://photos.prnewswire.com/prnh/20120924/562917-b )

Already used by several of the leading global agencies including Publicis, CDM and Draftfcb, the Agnitio platform has the advantage of being quicker, more flexible and far less resource heavy than other options available. Agencies with rights to the platform can easily create rich content, upload it, share it with their clients and then test it.

"As well as providing the best-in-class pull marketing platform to global healthcare companies directly, we are finding that their agencies are increasingly embracing our platform," says Morten Hjelmsoe, Founder and CEO of Agnitio. "In an ever more competitive healthcare market, the Agnitio platform has the key assets of speed, ease and flexibility to allow pharma companies and their agencies to personalise and optimise interactions with their customers, maximising time and building trusted relationships."

Agnitio licences allow users to create, upload and distribute presentations. They can also facilitate the approval of any new presentation before publishing to the iPad and allow the agency to check that the presentation is generating the correct data in line with its clients' requirements. Based on HTML5, the platform is excellent for localising content and import
'/>"/>

SOURCE Agnitio
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
2. UK supplier of graphenes announces exclusive sales agency agreement with leading USA distributor
3. DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
4. Awareness of Omega-3 Benefits Soars
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. BioSpace Spotlights Leading Life Science Community
7. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
8. iBioSeminars and iBioMagazine: Free, Online Biology Seminars and Short Talks by Leading Scientists
9. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
10. Johns Hopkins Health System is 100th healthcare Provider to Integrate OnBase With Leading Electronic Medical Record System
11. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 Respiratory therapy students will ... management of life-like respiratory ailments using the latest ... Grand Rapids-based, Michigan Instruments Inc. developers of the ... the respiratory simulation units to the pro-gram, which ... and Muskegon Community College are collaborating to offer ...
(Date:11/21/2014)... USA (PRWEB) November 19, 2014 The ... our lives was shared with more than 200 primary ... postgraduate students from the University of Otago Physics Department ... . The Otago students, members of the university’s OSA/SPIE ... Zealand in early September, giving children from small, rural ...
(Date:11/21/2014)... NY (PRWEB) November 20, 2014 The ... now available as an open access journal featuring the ... infrared fluorescent proteins to preserve photoresponsiveness in the retina ... Two-color fluorescent in situ hybridization using chromogenic substrates in ... for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... , June 1 /PRNewswire/ -- Pioneer Surgical Technology, ... follow up on the NuBac IDE feasibility study patients was presented at ... of Spine Surgery (SAS) in New Orleans by Domagoj ... , , ...
... June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... has received approval from the Belgian Federal Agency for ... 3 trial examining REOLYSIN in combination with paclitaxel and ... This is the same trial that was agreed to ...
... BOZEN, Sud-Tirol, Italy , May ... joint venture Health Robotics South East Asia Ltd.,scored two ... to deliver CytoCare-made accurate and sterile,oncology patient doses in ... Health,Robotics, CytoCare is the first and only robot in ...
Cached Biology Technology:Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand 2Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand 3
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... School of Medicine have found that new disease pathways ... 1 Gaucher disease, a rare genetic disorder in which ... liver/spleen enlargement, osteoporosis, bone pain, and increased risk of ... could lead to less expensive and more effective ways ...
... the cure for a fungus and parasite that affects millions ... of Missouri Chemistry Professor John Tanner would be the forensic ... model that could eventually solve the crime. Tanner, who also ... joined forces with Pablo Sobrado, an assistant professor of biochemistry ...
... CHAMPAIGN, Ill. University of Illinois chemists have ... in shoe bombs. It could lead to inexpensive, easy-to-use ... elsewhere. Triacetone triperoxide (TATP) is a high-powered explosive ... bombing attempts. TATP is easy to prepare from readily ...
Cached Biology News:Cheaper, more effective treatment of type 1 Gaucher disease possible 2X-ray diffraction may play key role in stopping 'kissing bug,' fungus 2Sniffing out shoe bombs: A new and simple sensor for explosive chemicals 2